<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830789</url>
  </required_header>
  <id_info>
    <org_study_id>20160610</org_study_id>
    <nct_id>NCT02830789</nct_id>
  </id_info>
  <brief_title>Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass</brief_title>
  <official_title>Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass in Order to Treat Secondary Hyperparathyroidism: A Clinical Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether calcium citrate or calcium carbonate are the optimal
      supplement to treat secondary hyperparathyroidism following Roux-en-Y gastric bypass
      operation.

      Half of the participants will be randomized to receive calcium citrate, while the other half
      will receive calcium carbonate. The study will be double blinded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parathyroid Hormone</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Se-ion-calcium</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-magnesium</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-phosphate</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-25-OH-vitamin D</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-calcitriol</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-24,25-(OH)2-vitamin D</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D binding protein</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procollagen type 1 N-terminal propeptide (P1NP)</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P-bone specific alkaline phosphatase</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cross-linked C-telopeptide (CTX)</measure>
    <time_frame>Change from baseline at 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h U-calcium</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h U-phosphate</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Roux-en-Y Gastric Bypass</condition>
  <condition>Hyperparathyroidism, Secondary</condition>
  <arm_group>
    <arm_group_label>Calcium Carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <arm_group_label>Calcium Carbonate</arm_group_label>
    <other_name>Unikalk Forte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium Citrate</intervention_name>
    <arm_group_label>Calcium Citrate</arm_group_label>
    <other_name>Unikalk Citrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet manufactured to mimic a calcium carbonate tablet</description>
    <arm_group_label>Calcium Carbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y gastric bypass</intervention_name>
    <description>Roux-en-Y gastric bypass surgery at least 12 months before study inclusion</description>
    <arm_group_label>Calcium Carbonate</arm_group_label>
    <arm_group_label>Calcium Citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Roux-en-Y gastric bypass operation ≥12 months ago

          -  Parathyroid hormone &gt; 6.9 pmol/l

          -  Vitamin D &gt; 50 nmol/l

          -  P-Calcium [1.18-1.32] mmol/l

        Exclusion Criteria:

          -  Liver disease

          -  Renal disease

          -  Hypercalcemia

          -  Untreated thyroid disease

          -  Parathyroid disease except secondary hyperparathyroidism

          -  Use of diuretics, bisphosphonates, calcitonin, teriparatide, oral corticosteroids,
             anabolic steroids, calcimimetics, lithium, strontium, denosumab or anticonvulsants
             within 1 year of inclusion

          -  abusing alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Enodocrinology and Internal Medicine, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Lene Ring Madsen</investigator_full_name>
    <investigator_title>PhD student, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

